Immune checkpoint inhibitor-related myocarditis in patients with lung cancer
The presentations of ICIs-related myocarditis in lung cancer are mainly possible myocarditis and probable myocarditis, which have a mild impact on the prognosis. More cycles of ICI treatment accompany the longer the PFS and OS, as a protective factor. Anti-PD1 therapy and older age may be protective factors for ICI-related myocarditis.
Authors
- Guangming Tian
- Di Wu (ORCID: https://orcid.org/0000-0001-9640-0516)
- Xiaoling Chen (ORCID: https://orcid.org/0000-0002-2271-1140)
- Jian Fang (ORCID: https://orcid.org/0000-0002-1077-3686)
- Lan Mi (ORCID: https://orcid.org/0000-0002-2320-2225)
- Jindi Han
- Qianyun Hao
- Yang Wang (ORCID: https://orcid.org/0000-0002-0078-8585)
- Kai Wang (ORCID: https://orcid.org/0000-0001-9205-9250)
- Jun Nie
- Sen Han (ORCID: https://orcid.org/0000-0002-5891-5225)
- Xiangjuan Ma (ORCID: https://orcid.org/0000-0002-1118-3725)
- Ziran Zhang (ORCID: https://orcid.org/0000-0002-7835-8788)
- Ling Dai (ORCID: https://orcid.org/0009-0005-5386-9089)
- Wenli Cao
- Jieran Long
- Weiheng Hu
- Panpan Zhang (ORCID: https://orcid.org/0009-0009-4980-2462)
- Jie Zhang (ORCID: https://orcid.org/0009-0004-5173-9996)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University Third Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s12885-025-13997-1
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China
- Peking University
- Beijing Municipal Administration of Hospitals